GeneTether Therapeutics, Inc. (TSE:GTTX) has released an update.
GeneTether Therapeutics Inc. has reported a strong fiscal year for 2023, maintaining $1,364,000 in cash reserves and advancing its proprietary GeneTether™ platform despite tough market conditions. The company has engaged with new auditors, updated its strategic plan, and confirmed the efficacy of its technology through independent experiments. These developments position GeneTether for potential strategic growth and collaborations in the biotech field.
For further insights into TSE:GTTX stock, check out TipRanks’ Stock Analysis page.
